InDevR Revenue and Competitors

Boulder, CO USA

Location

$10M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • InDevR's estimated annual revenue is currently $3.6M per year.(i)
  • InDevR's estimated revenue per employee is $77,500
  • InDevR's total funding is $10M.

Employee Data

  • InDevR has 46 Employees.(i)
  • InDevR grew their employee count by 48% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2M130%N/AN/A
#2
$2.8M1813%N/AN/A
#3
$70.7M45611%N/AN/A
#4
$4.5M297%N/AN/A
#5
$4M260%N/AN/A
#6
$2.4M3129%N/AN/A
#7
$2M13-35%N/AN/A
#8
$2.8M1850%N/AN/A
#9
$9.1M5918%N/AN/A
#10
$4.5M29-6%N/AN/A
Add Company

InDevR is a global leader in progressive new analytical technologies that enable accelerated development and manufacturing of vaccines and other biotherapeutics. Key products include our VaxArray portfolio of our game-changing multiplexed potency assays for vaccines and the Cypher One system for digital imaging and automated interpretation of hemagglutination assays.

keywords:N/A

$10M

Total Funding

46

Number of Employees

$3.6M

Revenue (est)

48%

Employee Growth %

N/A

Valuation

N/A

Accelerator

InDevR News

2022-04-13 - Microarray Market to Witness Huge Growth by 2028 | Takara ...

... Arrayit, Takara Bio, BioGenex, LC Sciences, US Biomax, AXO Science, BioCat, Cepheid, GE Healthcare, InDevR & Qiagen etc.

2019-09-10 - InDevR Raises $7M in Series A Financing

InDevR, Inc., a Boulder, CO-based biotechnology company focused on developing and commercializing novel analytical technologies for biologic process development and monitoring, raised $7m in Series A round of equity financing. Adjuvant Capital made the investment. The company intends to use th ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M4624%N/A
#2
$7.5M46-2%N/A
#3
$10.7M46-6%N/A
#4
$6.4M4615%N/A
#5
$11.9M4612%N/A

InDevR Executives


NameTitle
Kathy RowlenCEO
Shannon RodriguezChief Operations Officer
Laura KuckExecutive Vice President and Co-founder
John BirksCo-founder/EVP
Erica DawsonVice President of Research and Development